SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A ...

SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional activation of biologics to create highly active and less toxic medicines, ...

Good Therapeutics spinout Bonum Therapeutics has raked in $93 million to develop a new class of conditionally active therapies, with backing from Roche's venture arm. Bonum, which means “good” in ...

Seattle-based Bonum Therapeutics designs therapies that can be administered systemically for targeted activation in the body. (Good Therapeutics Graphic) Seattle biotech startup Bonum Therapeutics ...

Bonum Bank Plc is the central credit institution of amalgamation of POP Banks. It is responsible for obtaining external funding for the POP Bank Group, handling payments and in addition it grants ...

TAMPA, FL, Oct. 25, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS)(“TRxADE” or the “Company”) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum ...

John Mulligan, PhD, founder and CEO at Bonum Therapeutics. Bonum Therapeutics, a biopharmaceutical startup that uses allosteric control to develop conditionally active and less toxic medications, has ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The move comes as the company ...

Russian forestry group Segezha has agreed to buy the Inter Forest company from Bonum Capital investment company for $515 million in a deal that would increase Bonum's stake in Segezha, Bonum said on ...

Bonum Capital has agreed to sell Inter Forest to Segezha Group for $515 million. Inter Forest is a Russian forest holding company. MOSCOW–(BUSINESS WIRE)–Bonum Capital, an international investment ...